5-HT Reuptake Blockade Triggers Pyroptosis in BRAF V600E Melanoma

Study Background and Research Question

Melanoma driven by the BRAF V600E mutation remains challenging to treat, particularly due to the rapid emergence of resistance to targeted therapies such as BRAF and MEK inhibitors, as well as immune checkpoint blockade (Li et al., 2026). The urgency for alternative approaches is compounded by the high rate of therapeutic failure and the psychological distress commonly experienced by patients. Recognizing these gaps, Li et al. set out to explore whether repurposing existing FDA-approved antidepressants could yield novel anti-melanoma strategies, with a particular focus on disrupting tumor survival mechanisms at the epigenetic and proteostatic levels.

Key Innovation from the Reference Study

The central innovation of Li et al.'s work is the identification of paroxetine hydrochloride (PH), a selective serotonin reuptake inhibitor (SSRI), as a potent inducer of pyroptosis in BRAF V600E-mutated melanoma. Unlike conventional cytotoxicity, pyroptosis is a form of inflammatory programmed cell death that can reshape the tumor microenvironment to favor anti-tumor immunity. The study uncovers that PH exerts its effects by blocking 5-hydroxytryptamine (5-HT, serotonin) reuptake, reducing histone serotonylation (H3Q5ser) at DNA repair gene promoters. This epigenetic remodeling undermines the cell's ability to repair DNA, leading to genomic instability, proteostasis disruption, ER stress, and ultimately, pyroptosis (Li et al., 2026).

Methods and Experimental Design Insights

Li et al. conducted a high-throughput screen of 90 FDA-approved antidepressants against melanoma cell lines harboring the BRAF V600E mutation. Paroxetine hydrochloride emerged as the most effective agent in reducing melanoma cell viability. The research team used a combination of molecular, proteomic, and epigenetic assays to dissect the mechanism:

• CRISPR/Cas9 and RNAi knockdown to interrogate the role of 5-HT and serotonylation machinery.
• ChIP-qPCR and mass spectrometry to quantify changes in histone H3Q5ser at DNA repair gene promoters.
• Comet assays and γH2AX staining to assess DNA damage accumulation.
• Immunoblotting and immunofluorescence for detection of cleaved GSDMD and other pyroptosis markers.
• Mouse melanoma models, including BRAFi/MEKi-resistant tumors, to evaluate in vivo efficacy and synergy with anti-PD-1 immunotherapy.

This multi-level approach enabled the team to connect serotonin transporter inhibition to epigenetic reprogramming and downstream cell death pathways.

Core Findings and Why They Matter

The study demonstrates several key findings:

• Paroxetine hydrochloride induces pyroptosis in BRAF V600E-mutated melanoma cells, even in those resistant to BRAF/MEK inhibitors (Li et al., 2026).
• PH disrupts histone serotonylation (H3Q5ser) at DNA repair gene promoters, impairing excision, homologous recombination, and mismatch repair pathways.
• Resulting genomic instability leads to proteostasis imbalance and ER stress, which together trigger canonical pyroptotic cell death, as indicated by cleavage of gasdermin D and release of inflammatory cytokines.
• PH enhances the efficacy of anti-PD-1 therapy in mouse models of BRAFi/MEKi-resistant melanoma, supporting its immunomodulatory potential.
• 5-HT is essential for melanoma cell survival through maintenance of DNA repair and proteostasis; its depletion sensitizes cells to genomic insult and cell death.

These findings highlight a mechanistic link between neurotransmitter signaling, epigenetic modification, and tumor cell vulnerability—expanding the conceptual framework for drug repurposing in oncology.

Comparison with Existing Internal Articles

The mechanistic insights from Li et al. intersect with ongoing advances in protein extraction and proteostasis research. Several internal articles, such as "Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Advanced Mechanisms", discuss the necessity of broad-spectrum protease inhibition for maintaining protein integrity during extraction, especially in workflows involving signaling pathway and phosphorylation analyses. The reference study's focus on proteostasis imbalance and ER stress underscores the importance of preventing proteolytic degradation when assessing labile proteins and post-translational modifications. Similarly, APExBIO's EDTA-Free Protease Inhibitor Cocktail is highlighted for its compatibility with phosphorylation and inflammasome studies, which are critical in dissecting cell death modalities like pyroptosis. These internal resources provide practical context for selecting reagents that preserve the biological features perturbed in Li et al.'s experimental systems.

Limitations and Transferability

While the study offers compelling evidence for repurposing paroxetine hydrochloride in BRAF V600E-mutated melanoma, several limitations should be acknowledged:

• The preclinical findings are primarily based on cell lines and murine models; translational relevance in human patients remains to be validated.
• Potential off-target effects of SSRIs in non-tumor tissues and the interplay with systemic neurotransmitter signaling are not fully explored.
• Proteostasis disruptions and ER stress may yield context-dependent outcomes in different tumor types or in the presence of varying microenvironmental cues.
• While the study implicates phosphorylation state changes and proteolytic activity in the cell death cascade, direct quantification of these processes during protein extraction was not within the study's scope.

Nonetheless, the mechanistic clarity around serotonylation, DNA repair, and protease activity offers a platform for designing future research that integrates biochemical workflows with translational oncology.

Protocol Parameters

• protein extraction protease inhibitor | 1X final concentration (diluted from 100X stock) | cell and tissue lysate preparation | Broad-spectrum inhibition of serine, cysteine, acid proteases, and aminopeptidases preserves post-translational modifications during lysis | workflow_recommendation
• Protease Inhibitor Cocktail EDTA-Free | 1X in DMSO | phosphorylation analysis, kinase assay compatibility | EDTA-free formulation avoids chelation of divalent cations, critical for studying enzymes requiring Mg²⁺ or Ca²⁺ | product_spec
• inhibition of serine and cysteine proteases | AEBSF (0.5 mM), E-64 (0.5 μM), Leupeptin (1 μM) | cell lysate stabilization | Specific inhibitor concentrations provide targeted blockade to minimize proteolysis during sample handling | product_spec
• protease inhibition in cell lysates | immediate addition post-lysis | all downstream protein/peptide analyses | Minimizes artifactual protein degradation and preserves native structure/function | workflow_recommendation

Research Support Resources

For researchers aiming to explore proteostasis, cell death mechanisms, or phosphorylation events in sensitive melanoma models, maintaining protein integrity during extraction is paramount. The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1007) from APExBIO offers a robust, ready-to-use solution for inhibition of serine and cysteine proteases, among others, while preserving compatibility with phosphorylation analysis and related enzymatic assays (source: internal_article). This resource is particularly suitable for workflows studying the intersection of DNA repair, proteostasis, and cell death in oncology and beyond.